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INTRODUCTION 
Since the description of HIV associated pulmonary 
hypertension (HIV-PH) by Kim and Factor in 1987, 
the prevalence of HIV-PH has been reported to be 
between 0.06-2% (1). This is far less common compared 
to the infectious complications associated with HIV 
disease. However, with widespread antiretroviral 
therapy (ART) rollout programmes, more people are 
now living with HIV hence the relative prevalence of 
non-infectious complications related to HIV disease 
are likely to increase. 
 HIV-PH has been documented to occur at all 
stages of the disease and its manifestations range 
from asymptomatic right ventricular dysfunction 
to overt right heart failure. There have been no 
large scale studies on the effects of ART on HIV-PH. 
Most treatment modalities currently in place are an 
extension of evidence from trials used to manage 
idiopathic pulmonary hypertension. 
 We present a case of HIV-PH to highlight 
the importance of the non infectious pulmonary 
complications associated with HIV disease. 
CASE REPORT 
A thirty year old female presented with an eight month 
history of progressively increasing shortness of breath 
at The Aga Khan University Hospital, Nairobi on the 
29th January 2008. She also reported associated lower 
limb swelling, facial pufﬁness and difﬁculty in lying 
on a ﬂat bed. In the last month prior to her admission, 
the shortness occurred even during bathing and 
dressing. She also had a nocturnal non productive 
cough. She was para 3+0 and all her pregnancies 
were uneventful. She denied any history of a wheeze, 
haemoptysis, rash, oral or genital sores. She had no 
history of febrile illness, night sweats or weight loss. 
She had been started on frusemide and candensartan 
for presumed heart failure at the nearest health facility 
and reported temporary relief of symptoms, until one 
month prior to presentation. 
 Examination revealed an afebrile ill looking 
young lady whose vital signs were as: BP 110/62mmHg 
supine, P 132 bpm regular, of low volume and normal 
character, RR 20 breaths/ min. General examination 
revealed oral candidiasis and bipedal lower limb 
pitting oedema. No joint swelling or deformity and 
no skin rashes were found. 
 Pertinent cardiovascular ﬁndings included an 
elevated jugular venous pulsation with a prominent v 
wave. Her apex beat was undisplaced and her cardiac 
impulse felt normal. She had a left lower parasternal 
lift and a palpable P2. Cardiac auscultation conﬁrmed 
a loud P2 and a pansystolic murmur in the left lower 
sternal border which was accentuated on inspiration. 
The rest of her systemic exam was non contributory. 
A clinical diagnosis of right heart failure with 
pulmonary hypertension and immunosuppression 
was made. 
 A resting l2-lead ECG demonstrated an 
incomplete right bundle branch block and evidence 
of right atrial overload. Echocardiogram revealed a 
moderately enlarged right ventricle and atrium with 
paradoxical septal motion. She had moderate- severe 
tricuspid regurgitation with an estimated pulmonary 
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SUMMARY 
With the advent of highly active antiretroviral therapy, there has been a signiﬁcant change 
in the epidemiology of pulmonary disease in HIV/AIDS. The relative prevalence of 
non-infectious manifestations is likely to rise. HIV associated pulmonary hypertension 
(HIV-PH), albeit low prevalence, is associated with signiﬁcant morbidity and mortality. 
Presently, despite having scanty evidence on the management modalities of HIV-PH, 
evidence extrapolated from idiopathic pulmonary hypertension is being utilised to 
effectively manage some of these patients. Efforts should therefore be made to screen, 
diagnose and treat these patients. A case of a thirty year old female with HIV disease 
and severe pulmonary hypertension is presented. 
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arterial pressure of 80mmHg. Her left ventricular 
ejection fraction was 50% with normal mitral and 
tricuspid valve anatomy. No atrial septal defect or 
any other cardiac shunts were found. 
 Full blood count and ESR, renal and liver 
functions were normal, and her peripheral blood 
ﬁlm did not reveal any evidence of an underlying 
haemolytic disorder. After counselling and testing, 
an ELISA for HIV was positive, CD4 count was 
312cells/mm3 and a plasma viral load 75,000 copies/
mm3. She was hepatitis B surface antigen negative. 
A CT pulmonary angiogram ruled out pulmonary 
thromboembolic disease. 
 She was commenced on diuretics, antifungals, 
anticoagulation and later sildenaﬁl introduced. She 
experienced signiﬁcant symptomatic improvement. 
On the ﬁfth hospitalisation day the patient was able 
to ambulate freely in the ward, and perform her 
personal activities without signiﬁcant limitation. She 
was discharged home on 5th February 2008, eight 
days after hospitalisation on frusemide, warfarin, 
tenofovir/emtricitabine and efavirenz. 
 On out-patient follow up three months later, 
the patient reported to be able to climb two ﬂights 
of stairs and perform her activities of daily living 
comfortably. She was to have an echocardiogram 
repeated in 12 months from her initial presentation 
for estimation of her pulmonary arterial pressures 
as a follow up of the efﬁcacy of treatment. The 
frequency of echocardiographic follow-up was 
based on the patient living away from Nairobi, 
and concomitant ﬁnancial strain on performing six 
monthly echocardiographic assessments. However, 
improvement in her dyspnoea severity, as assessed by 
her New York Heart Association criteria, about three 
months into therapy is a strong clinical indicator of 
therapeutic efﬁcacy and this parameter in addition 
to yearly echocardiography will be utilised for her 
follow up. 
DISCUSSION 
Pulmonary hypertension (PH) is a relentlessly 
progressive disease leading to right heart failure and 
death. With a worldwide prevalence of HIV disease 
estimated at 40 million (2), and that of    HIV-PH at 0.06-
2.0% (1), HIV disease may be among the most common 
cause of pulmonary hypertension worldwide. 
 Reports from other parts of Africa, however, 
suggest a much higher prevalence of HlV-PH at about 
5% (3). This goes to reﬂect the potential magnitude of 
HIV -PH in sub Saharan Africa, which houses over 
two-thirds of the global HIV burden (4). Despite these 
alarming ﬁgures, a pubmed search did not reveal 
any citations from Kenya on the prevalence of this 
complication associated with HIV disease. 
 A diagnosis of HIV-PH was made in this 
patient after exclusion of the common secondary 
causes of PH, as connective tissue disease, chronic 
thromboembolic disease and haemolytic anaemias. 
Due to the age bracket the index patient presented 
in, connective tissue disease fell high on the list. 
However, her clinical history, physical examination 
and supportive laboratory and radiological evidence 
were not in keeping for a connective tissue disease, 
chronic thromboembolism or haemolytic anaemias. 
Since the potential causes for PH are numerous and 
investigations to rule out each would be superﬂuous, 
it is imperative to obtain a good clinical history and 
perform a thorough clinical evaluation to narrow 
the differential causative agents as performed in this 
patient. 
 Pulmonary arterial hypertension, of which 
HIV -PH is a sub entity, deﬁnes an increase in mean 
pulmonary arterial pressure related to an arteriopathy 
of the pulmonary vasculature. Patients with HIV -PH 
have plexogenic lesions similar to diseases associated 
with pulmonary arterial hypertension. 
 Majority of the patients clinically present with 
dyspnoea on exertion (85%), pedal oedema (20-30%) 
and a non-productive cough (19%). The interval 
duration between symptom development and 
diagnosis is reported at six months (5). This data 
is in line with the clinical symptoms and duration 
between symptom onset and diagnosis in the index 
patient. There is also no correlation between the CD4 
count or plasma viral load and the development of 
HIV-PH (6,7). 
 In terms of pathogenetic mechanisms, there is 
no evidence incriminating human immunodeﬁciency 
virus (HIV) to be directly infecting pulmonary 
vascular endothelial cells (8,9). However, viral 
antigens such as GP120 and Nef, are thought to 
stimulate growth and proliferation (8,10,11). The 
other plausible mechanism includes induction 
by HIV infection of a chronic inﬂammatory state 
with release of growth promoting cytokines which 
stimulate smooth muscle hypertrophy and increase 
pulmonary vascular resistance (12,13). 
 Treatment of patients with HIV-PH is based on 
symptomatology, functional class and the severity of 
PH. Although vasodilator agents increase survival in 
patients with idiopathic pulmonary hypertension, 
the impact of these therapies on HIV-PH is unknown 
(14,15). 
 Nunes et al (l6) reported better survival in 
patients on epoprostenol infusion. In another 
smaller study, Petitpretz  et al (6) also reported 
signiﬁcant improvement in the haemodynamics in 
patients on epoprostenol. Epoprostenol has well 
described adverse effects, as well as its difﬁculty 
in administration. We therefore chose sildenaﬁl, a 
phosphodiesterase-5-inhibitor, which has shown 
some short term efﬁcacy in case reports of patients 
with HIV-PH (17-19). A potential problem with 
sildenaﬁl is that its levels may signiﬁcantly increase 
by concurrent use of protease inhibitors, hence the 
choice of efavirenz in our patient. 
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 The other potential choice to reduce pulmonary 
arterial pressure would include endothelin antagonists, 
as bosentan. Like all the other agents, scanty data exists 
in HIV-PH (20-22). In view of this, its unavailability 
in our region, and the exorbitant costs of the drug, 
our patient was not started on it. 
Figure 1
Apical 4 chamber view demostrating an enlarged right 
atrium and enlarged right atrium and ventricle
 The role of antiretroviraI therapy in patients 
with HIV-PH is not clear since large scale trials are 
lacking. Conﬂicting evidence exists in literature on 
the role of ART in HIV-PH. Zuber et al (1) in their 
retrospective study showed a decreased incidence of 
PH following the introduction of HAART; in addition, 
they also demonstrated reduced mortality associated 
with PH. However, other studies (7,14) failed to 
demonstrate an effect of ART on HIV-PH. Nunes 
et al (7) observed that survival rates were worse in 
patients receiving HAART alone compared to HAART 
and epoprostenol. Therefore until well conducted 
multicenter prospective studies are conducted the 
survival beneﬁt of HAART in patients with HIV -PH 
cannot be deﬁnitively concluded.
Figure 2
 
 This case highlights the presence of HIV-PH 
whose mortality is two fold higher in HIV patients 
without pulmonary hypertension (23). It also brings 
to the fore the potential problems our HIV patients 
may now present with, since a large proportion of 
patients on HAART are now living much longer 
with HIV disease. It also calls for larger studies in 
our region to build up regional evidence in order to 
better the management of such patients. 
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GOOD CLINICAL LABORATORY PRACTICE (GCLP) 
COURSE AT 
KENYA AIDS VACCINE INITIATIVE 
Description: 
This course is designed to prove 
comprehensive guidance and practical 
help for those who are implementing Good 
Clinical Laboratory Practice in laboratories 
which undertake the analysis of samples 
from clinical trials. 
 The course will address the current 
regulatory framework for laboratory work 
in support of clinical trials with reference 
to the ICH Guideline for Good Clinical 
Practice, the Clinical EU Trials Directive and 
related regulations and guidance. The course 
will also draw on the BARQA guidance 
document on Good Clinical Laboratory 
Practice (GCLP). 
The course is structured to encourage delegates to: 
√  Discuss and develop ideas. 
√  Solve speciﬁc problems. 
√  Examine particular aspects of GCP and 
GCLP. 
Beneﬁts include: 
√ Guidance on the interpretation and 
application of GCLP within the 
framework of Good Clinical Practice 
(GCP). 
√ Understand how GCLP ﬁts within a 
clinical (GCP) programme. 
√ Practical help on how to implement GCLP 
within a clinical research laboratory. 
√ An opportunity to update your knowledge 
of GCLP with the current interpretation 
of requirements 
√ Access to an experienced panel of 
speakers. 
√ An opportunity to improve your 
understanding of the GCLP requirements 
as they are applied in different 
situations. 
Who should attend? 
Laboratory managers, analysts, investigators, 
trial co-ordinators, monitors and auditors 
working in: 
√  Pharmaceutical company laboratories 
√  Central laboratories 
√  Contract Research Organisations 
√  Hospital Laboratories 
√  Clinics 
√  Investigator sites 
Contacts: 
Kenya Aids Vaccine Initiative, 
P. O. Box 19676-00202, Nairobi 
Tel:  2725405/2717694/0722207417 
Fax:  2714613 
Email:  fbashir@kaviuon.org 
Website:  www.kaviuon.org
Duration of the course: 4 DAYS 
Minimum No. of participants: 10 
